Abstract | Immunological identity is traditionally defined by genetically encoded antigens, with equal maternal and paternal contributions as a result of Mendelian inheritance. However, vertically transferred maternal cells also persist in individuals at very low levels throughout postnatal development. Reciprocally, mothers are seeded during pregnancy with genetically foreign fetal cells that persist long after parturition. Recent findings suggest that these microchimeric cells expressing non-inherited, familially relevant antigenic traits are not accidental 'souvenirs' of pregnancy, but are purposefully retained within mothers and their offspring to promote genetic fitness by improving the outcome of future pregnancies. In this Review, we discuss the immunological implications, benefits and potential consequences of individuals being constitutively chimeric with a biologically active 'microchiome' of genetically foreign cells.
The unique composition of genetically encoded antigenic traits in each individual has traditionally been used to define their immunological identity. This binary classification of antigens as either 'self ' or 'non-self ' has established a conceptual framework for evaluating how the adaptive immune system responds to microbial infection, or to antigen stimulation in other contexts such as immunization or transplantation 1, 2 . Importantly, however, the classical immunological tenets of self-tolerance, which have been based primarily on the analysis of highly inbred animal strains, do not properly reflect the genetic diversity of outbred populations, in which each individual contains a distinct immunological signature that is defined by unique MHC haplotypes and other minor alloantigens. This limitation of investigating tolerance exclusively using genetically identical, inbred animals is magnified when addressing the immunological changes that occur during pregnancy, when expanded maternal tolerance to genetically discordant fetal tissue is likely to be essential for successful reproduction.
The physiological exposure of individuals to foreign antigens during pregnancy and early life development has been used to establish working models of immunological identity and tolerance. In the 1940s, Ray Owen recognized the plasticity of immune tolerance, which naturally extends beyond genetically encoded self antigens, as a result of experiments showing expanded blood group compatibility among dizygotic twin cattle that had mixed circulatory systems during in utero development 3 . In the 1950s, Sir Peter Medawar articulated the immunological conundrum that is associated with viviparity by describing the contrast between the rapid rejection of allogeneic skin grafts and the persistence of fetal tissues in mothers during pregnancy 4 . Thus, pregnancy activates unique adaptations in mothers in order to maintain fetal tolerance. Given the dominant role of reproductive fitness in trait selection, adaptations that reinforce fetal tolerance and promote maternal well-being are likely to be engrained within the reproductive process as a result of refining positive selection. Accordingly, we propose that further dissection of how maternal-fetal conflict is averted has the exciting potential to not only reveal new strategies for improving pregnancy outcomes but also provide fundamental insights into how immune tolerance works in other biological contexts.
Many of the known mechanisms that maintain fetal tolerance function at the maternal-fetal interfaceincluding the production of immunosuppressive molecules, the exclusion of immune cells through chemokine gene silencing, reduced complement deposition and the entrapment of professional antigen-presenting cells. These have recently been summarized elsewhere [5] [6] [7] [8] and are not discussed further here. However, given the limited macroscopic anatomical distribution of fetal tissues in women during pregnancy, it remains unclear why systemic immunological changes are also involved. In this context, a remarkable, but somewhat under appreciated, aspect of mammalian pregnancy is the bidirectional transfer and systemic seeding of small numbers of genetic ally foreign cells, termed microchimeric cells, between the mother and offspring.
Fetal tolerance
The processes that allow fetal cells and tissues that express genetically foreign paternal antigens to avoid immune rejection and coexist in harmony inside expecting mothers during pregnancy.
Microchimeric cells
Rare cells found in one individual that originate from another individual and are genetically distinct from the host individual.
Non-inherited maternal antigens
(NIMAs). The half of genetically encoded maternal antigens that are not transmitted to an offspring by classical Mendelian inheritance.
Beginning early in pregnancy, fetal cells are found in the maternal blood and tissues, with the number of these cells progressively increasing until term 9, 10 . Reciprocally, maternal cells are found in human fetal tissues from the second trimester of pregnancy onwards 11, 12 . Perhaps more remarkable are the long-term persistence of these genetically discordant fetal cells in mothers many years after pregnancy and the retention of maternal cells in offspring throughout postnatal development into adulthood 13, 14 . Despite near-uniform agreement that all individuals contain these microchimeric cells, surprisingly little is known regarding their biological function and molecular properties. These knowledge gaps are primarily due to the lack of tools for the experimental manipulation and consistent identification of these exceptionally rare cells (TABLE 1) . Nonetheless, fetal microchimerism (FMC) and maternal microchimerism (MMC) have been increasingly shown to occur for various haemato poietic, undifferentiated and tissue-restricted cell types (see Supplementary information S1 (table) ). Interestingly, recent findings suggest that these microchimeric cells are not accidental 'souvenirs' of pregnancy but instead are purposefully retained to help to promote the success of future pregnancies 15 . Thus, further investigating the fundamental biology of microchimeric cells -including their origins and the mechanisms by which they evade immunological rejection -has the potential to redefine immunological identity to also include genetically foreign but familially relevant antigenic traits. In this Review, we discuss accumulating evidence regarding the persistence, cellular identity and molecular phenotype of microchimeric cells; their potential bio logical benefits and harmful consequences; and the broader immunological implications of considering individuals as being constitutively chimeric.
Expanded immune tolerance during pregnancy
For placental mammals, prolonged in utero maturation promotes the survival of offspring, while minimizing the wasted allocation of resources to non-surviving offspring. However, the close physical localization of maternal and fetal tissues during in utero maturation also highlights the immunological conundrums of why maternal immune cells do not reject genetically foreign fetal tissues and how fetal immune components that are constitutively exposed to maternal tissues adapt to the presence of genetically foreign non-inherited maternal antigens (NIMAs). In this section, we discuss the expanded immune tolerance that averts maternalfetal conflict during pregnancy from the perspective of microchimeric cells.
Maternal tolerance to paternal-fetal antigens. Despite the many localized mechanisms that occur at the maternal-fetal interface to avert immune rejection of the high density of fetal cells that are contained within the pregnant uterus [5] [6] [7] [8] , potent immunological changes also occur systemically in women during pregnancy. For example, the severity of autoimmune disorders that affect non-reproductive tissues, such as rheumatoid arthritis and multiple sclerosis, markedly improves in women during pregnancy 16, 17 . Similarly, the serological response to inactivated influenza vaccine is blunted during human pregnancy 18, 19 . These systemic changes in immune reactivity that occur during pregnancy prob ably extend to maternal immune components that have specificity for fetus-expressed antigens, given the FMC that results from the widespread seeding and retention of genetically foreign fetal cells in the peripheral tissues of mothers (FIG. 1a) .
Early studies that used various methods (TABLE 1) to identify fetal microchimeric cells that express unique paternally derived markers showed that fetal cells are present among maternal peripheral blood mononuclear cells (PBMCs) at a frequency of 1 in 10 3 cells by 14-15 weeks of gestation 20 and that fetal cells can be detected in maternal blood as early as 7 weeks gestation, which is before the complete establishment of the fetal placental vasculature 21 . The number of fetal cells in maternal blood progressively increases throughout pregnancy, reaching peak levels of more than 100 fetal cells per millilitre of maternal blood at parturition 21, 22 . Similarly, cells containing fetal DNA have been found in the cadaveric lung, spleen, liver, kidney and heart tissues of women during pregnancy 9 . Importantly, fetal microchimeric cells are intact cells, and they are a completely distinct source of fetal DNA from the placentaderived, cell-free fetal DNA that is present in the serum of mothers during pregnancy and that is increasingly being used for prenatal analysis.
The transfer of fetal cells to mothers during pregnancy is highly conserved and is thought to occur in all placental mammalian species 23 . For rhesus macaque non-human primates, fetal cells are found among maternal PBMCs during the second and third trimesters of pregnancy, and in various maternal tissues -including the heart, liver and spleen -at the time of term delivery 24 . Similarly, in mice, fetal cells of many unique cell types are found within multiple maternal tissues (see Supplementary information S1 (table)); fetal cells begin accumulating in these tissues shortly after implantation, and their numbers reach a peak level of 1 fetal cell per 10 4 -10 6 maternal cells by late gestation 10, 25 . The progressively increasing number of fetal cells within various maternal tissues during pregnancy correlates with the systemic expansion of immunosuppressive CD4 + regulatory T (T reg ) cell populations 26 . Circulating maternal T reg cells begin to accumulate in mice the day after conception, and their numbers increase approximately twofold by midgestation during healthy pregnancies [26] [27] [28] . By contrast, fetal wastage is associated with defective maternal T reg cell accumulation in abortion-prone matings between defined strains of inbred mice, or with a reduction in the suppressive capacity of T reg cells on a per cell basis in the context of prenatal infection [29] [30] [31] . Allogeneic pregnancies promote a greater expansion of maternal T reg cell populations than do syngeneic pregnancies, which highlights the importance of maternal-fetal MHC mismatch in driving maternal T reg cell accumulation 27, 28 . The modest expansion of maternal T reg cell populations that does occur during syngeneic pregnancies is thought to reflect a maternal mismatch to Y-chromosome-expressed fetal allo antigens 32 , or the response to self-antigen stimulation 33 , and may coincide with the increased need for tissue repair and homeostasis during pregnancy 34, 35 . By investigating pregnancy outcomes in mice after the partial depletion of maternal T reg cells to prepregnancy levels, it was confirmed that a sustained increase in maternal T reg cell numbers is necessary to avert fetal wastage in allogeneic but not syngeneic pregnancies 28, 36 . Interestingly, blunted systemic expansion and decidual accumulation of maternal T reg cell populations are also associated with complications in human pregnancy such as pre-eclampsia and spon taneous abortion 26 , although there is no clear-cut evidence that this association is not simply correlative. Thus, the expanded immune tolerance during pregnancy in mothers that is required to accommodate foreign paternal-fetal antigens -both locally in the uterus and systemically in response to seeded fetal microchimeric cells -parallels the systemic accumulation of maternal T reg cells, although further work is required to establish the necessity of expanded maternal T reg cell populations in human pregnancy.
Antigen-specific tools that track how mothers uniquely respond to stimulation with fetus-expressed antigens show that pregnancy-induced immunological changes are most pronounced for maternal immune components that have paternal-fetal specificity 28, 30, 36, 37 . For example, during pregnancies sired by transgenic male mice that express defined model antigens, most fetus-specific CD8 + T cells in the mother undergo clonal deletion and do not acquire cytotoxic effector properties despite extensive proliferation 37 . The remaining fetus-specific CD8 + T cells express low levels of CXCchemokine receptor 3 (CXCR3), and are restricted from accessing the maternal-fetal interface through epigenetically silenced expression of the genes encoding CXCchemokine ligand 9 (CXCL9) and CXCL10 by decidual stromal cells 38, 39 . By contrast, maternal CD4 + T cells specific for fetal antigens proliferate and preferentially differentiate into T reg cells, as demonstrated by their increased expression of forkhead box protein P3 (FOXP3) 36 . The necessity of fetus-specific T reg cells for successful pregnancy in mice is demonstrated by the fetal loss that occurs after blocking T reg cell differentiation selectively among maternal CD4 + T cells that have fetal specificity 40 . The accumulation of fetus-specific FOXP3 + CD4 + T cells is primarily driven by peripherally induced T reg cells, rather than by the proliferation of thymus-derived T reg cells, as FOXP3 − donor CD4 + T cells transferred to female mice before pregnancy readily proliferate and upregulate FOXP3 expression upon fetal antigen stimulation 36 . Similarly, fetal wastage occurs in mice with targeted deletion of the enhancer conserved non-coding DNA sequence element 1 (CNS1), which is required for induced Foxp3 expression 41 . Interestingly, CNS1 is highly conserved across placental mammals, but is absent in marsupials and egg-laying mammals, which suggests that viviparity may have co-evolved with the capacity for peripherally induced T reg cell differentiation 41 . Thus, considering that humans share with other placental mammals, such as mice, the need to avert maternal-fetal immunological conflict during pregnancy, animal pregnancy models that allow for experimental manipulation are invaluable tools for investigating how immune tolerance functions during the reproductive process, although speciesspecific differences limit the direct translation of these findings into the setting of human pregnancy.
Fetal tolerance to NIMAs. In addition to maternal exposure to fetal antigens, the fetus is reciprocally exposed to an equally vast array of genetically foreign NIMAs during in utero maturation. Nascent T cells begin seeding human fetal lymphoid tissue by gestational week 10, and they progressively accumulate throughout in utero development 42 . However, immunological attack of and damage to genetically foreign maternal tissues does not occur even though fetal T cells are capable of alloantigen-induced proliferation 12 . Instead, fetal CD4
+ T cells preferentially undergo T reg cell differentiation in response to NIMA stimulation, and this expanded fetal T reg cell pool is thought to avert maternal-fetal conflict by suppressing the function of NIMA-specific effector T cells 12 . Although the factors that are responsible for this shift from T cell sensitization to tolerance during in utero development remain largely undefined, an interesting parallel occurrence is the vertical transfer and persistence of genetically discordant, maternal microchimeric cells in offspring (FIG. 1b) . For example, cells with two X chromosomes, which are therefore presumed to be of maternal origin when found in males, are consistently Nature Reviews | Immunology found in the cord blood of human male offspring 43 . Furthermore, maternal cells have been identified in various human fetal tissues 11, 12, 44 . Interestingly, in humans, the kinetics of maternal cell seeding in the fetus parallel the maturation of the fetal thymus and peripheral lymphoid tissues 42, 45 , which suggests that vertically transferred maternal cells might have a role in delivering NIMAs to developing fetal immune cells so that they can prime tolerogenic responses.
The vertical transfer of maternal cells to offspring is widely conserved across placental mammalian species, despite marked differences in the maturation state of fetal adaptive immune cells at the time of birth 42, 46, 47 . In rodent offspring, in which peripheral B and T cells are not detected until after birth, maternal cells are nonetheless present in the fetus by midgestation, and they progressively accumulate in various fetal tissues 48, 49 . Accordingly, although vertically transferred maternal cells are an important source of NIMAs that have been implicated in averting maternal-fetal conflict in humans and other species that have functional fetal adaptive immune cells at birth 12, 42 , this explanation is probably incomplete because maternal cells are similarly transferred to offspring in species in which adaptive immune cells do not develop until after birth 48, 49 . Thus, the highly conserved nature of pregnancy-induced microchimerism across mammalian species suggests that additional biological advantages, aside from supporting maternal-fetal tolerance during pregnancy, promote the maintenance of these phenomena during reproduction.
Persistent immune tolerance after parturition
Despite the anatomical separation of fetal and maternal tissues at the time of birth, expanded immune tolerance primed by pregnancy persists in both mothers and offspring. This may explain why vertically transferred maternal cells are retained in offspring throughout postnatal development and why fetal cells persist in mothers decades after giving birth, even though the rarity of these cells may preclude their consistent identification in more limited tissue samples from some individuals. In this section, we discuss how pregnancy imprints expanded bidirectional tolerance in mothers and their offspring in relation to the persistence of microchimeric cells.
Postnatal tolerance to NIMAs. Postnatal NIMA-specific tolerance in humans gives rise to some remarkable immunological phenotypes, including reduced sensitization to erythrocyte Rhesus factor (Rh) antigens among Rh-negative women born to Rh-positive mothers 50 , and suppressed serological sensitization to noninherited maternal HLA antigens in transfusion-dependent individuals who develop antibodies against almost all other HLA alloantigens 51 . In a ground-breaking analysis of the outcomes of kidney allografts, long-term graft survival was shown to be significantly improved in NIMAmatched sibling donor-recipient pairs 52 . The severity of graft-versus-host disease (GVHD) after bone marrow transplantation is also reduced in recipients of NIMAmatched donor stem cells 53, 54 . The postnatal persistence of NIMA-specific tolerance is similarly recapitulated in animals. For example, the long-term survival of cardiac H-2 d allografts occurs in recipient mice exposed to H-2 d as a NIMA compared with the rapid rejection of these grafts in recipient mice that have not been exposed to H-2 d during development 46 . Likewise, the severity of GVHD is reduced in mice after the engraftment of allogeneic stem cells from donor mice with developmental exposure to NIMAs that overlap with foreign antigens in recipient mice 55 . Animal cross-fostering studies and parental breastfeeding surveys of human transplant recipients show that the improved survival of NIMA-matched allografts is negated when postnatal NIMA exposure through breastfeeding is eliminated, which indicates that breastfeeding is essential for the maintenance of NIMA-specific tolerance in offspring 46, 56 . However, the postnatal in gestion of maternal cells or soluble maternal MHC molecules alone is insufficient to prime NIMA-specific tolerance, as such ingestion does not improve the survival of NIMA-matched donor allografts in mice that have not been exposed to NIMAs in utero 46, [57] [58] [59] . Thus, NIMAspecific tolerance requires exposure to maternal cells both prenatally and postnatally through breastfeeding.
The highly conserved postnatal persistence of MMC across species suggests that important teleological benefits may promote the maintenance of NIMA-specific tolerance in offspring 12, 46, 47 . In this regard, although the vertical transfer of maternal cells probably protects against maternal-fetal conflict during in utero development by conditioning fetal immune cells for NIMAspecific tolerance 12, 42 , a perplexing question is why MMC persists in offspring after birth (FIG. 1b) . In adult humans and mice, maternal microchimeric cells are distributed across a range of tissues 14, 23, 59, 60 (FIG. 1b) , and this persistence of MMC parallels the systemic retention of NIMAspecific T reg cells 12, 15, 61 . Reciprocally, a rapid decline in the number of NIMA-specific FOXP3 + CD4
+ T reg cells occurs in mice following the depletion of maternal microchimeric cells, which suggests that ongoing postnatal NIMA exposure maintains the expanded accumulation of NIMA-specific T reg cells in offspring 15 . Interestingly, by investigating the outcomes of next-generation pregnancies in mice, it has been observed that susceptibility to fetal wastage triggered by disruptions in fetal tolerance -induced by either infection with the + T cells -is markedly reduced during pregnancies sired by males that express NIMA-matched MHC haplotypes compared with pregnancies sired by mismatched males 15 . Protection against fetal wastage was associated with the robust expansion of NIMA-specific maternal T reg cell populations that had overlapping paternal-fetal specificity compared with fetus-specific T reg cells that did not have overlapping NIMA specificity. Reciprocally, the depletion of maternal microchimeric cells from female mice overturned this protection against fetal wastage during a subsequent pregnancy and eliminated the expanded accumulation of NIMA-specific T reg cells 15 . These cross-generational reproductive benefits of NIMA-specific tolerance suggest that, together with the transfer of maternal genetic traits encoded by homologous chromosomes through Mendelian inheritance, the vertical transfer and postnatal retention of maternal cells in offspring promotes the genetic survival of non-inherited maternal traits by reinforcing fetal tolerance to these during nextgeneration pregnancies 15 . However, as the protection against fetal wastage was shown for the complete overlap of MHC haplotype alleles between NIMAs in mothers and fetus-expressed paternal antigens using defined strains of inbred mice for mating 15 , it will be necessary to further investigate the degree of protection achieved when the antigenic overlap is restricted to individual MHC loci and/or other alloantigens; such restricted antigenic overlap would be more likely to occur than complete overlap among humans and individuals in outbred populations.
Postpartum maternal memory to fetal antigens.
Similarly to the postnatal persistence of maternal cells in offspring, fetal cells are also retained in various maternal tissues after parturition (FIG. 1a) . For example, Y-chromosome DNA can be amplified from maternal PBMCs up to 27 years after giving birth to a son 13 . Fetal cells that can be identified by Y-chromosome or HLA-haplotype DNA persist in many lymphoid and non-lymphoid tissues, and among multiple cell types, in mothers after parturition (as reviewed in REFS 62, 63 ; also see Supplementary information S1 (table)). The retention of fetal cells in maternal tissues is also highly conserved across mammalian species, which suggests that there are likely to be biological benefits that drive the maintenance of tolerance to fetal antigens in mothers after pregnancy 10, 24, 64 . Analogously to how the persistence of maternal microchimeric cells in female offspring promotes the genetic survival of non-inherited maternal traits by enforcing fetal tolerance to these during next-generation pregnancies 15 (FIG. 1c) , a provocative hypothesis is that the fetal microchimeric cells that are retained in mothers after pregnancy may similarly reinforce fetal tolerance during future pregnancies. This notion is supported in humans by the partner-specific protective benefits of a prior pregnancy against complications in future pregnancies. For example, the incidence of pre-eclampsia is reduced during second pregnancies sired by the same father who sired the first pregnancy, whereas these protective benefits are eliminated when the second pregnancy is sired by a new male partner 65, 66 . These human partner-specific benefits of prior pregnancy correspond in animals to the persistence of fetus-specific maternal T reg cells after parturition, their more rapid secondary expansion after restimulation with fetal antigen, and protection against the fetal wastage that is induced by partial depletion of maternal FOXP3 + CD4 + T reg cells in a secondary pregnancy compared with in a primary pregnancy 36 . Thus, the persistence of fetal micro chimeric cells that express pre-existing fetal antigens may represent an altruistic act of first children to promote tolerance in their mothers to genetically similar future siblings 67 and conflict with genetically discordant siblings 68 . The protective benefits of prior pregnancy in humans can wane with progressively increased inter-pregnancy intervals 69, 70 , which suggests that the durability of expanded T cell tolerance primed by fetal microchimeric cells might be reduced compared with that primed by maternal microchimeric cells. By contrast, serological sensitization to fetus-expressed HLA antigens primed by pregnancy in mothers is considerably more durable, but surprisingly is not known to be associated with any positive or negative effect on the outcomes of subsequent pregnancies 71, 72 . Whether this reflects the balanced effects of antibodies -which can promote the rejection of genetically foreign tissues after transplantation, but can also suppress rejection through accommodation 73 or enhancement 74 -remains to be established. Nonetheless, considering that females can become pregnant multiple times, it will be important to establish how maternal adaptive immune memory components and fetal microchimeric cells retained from prior pregnancies each respond to newly seeded fetal cells during subsequent pregnancies.
Redefining immunological identity
With an increasing appreciation of the active crosstalk that occurs between host adaptive immune components and commensal microorganisms, the paradigm that immunological identity is exclusively defined by genetically encoded self antigens has already undergone a revision to include the expanded repertoire of 'extended-self ' antigens that are encoded by the micro biome 75 . Given the postnatal persistence of MMC in adult individuals, and the additional seeding of adult females with fetal microchimeric cells during pregnancy, these genetically discordant, microchimeric cells can analogously be viewed as a biologically active 'microchiome' that contains an expanded repertoire of familially relevant, extended-self antigens (FIG. 2) . In turn, changes in the number, phenotype or distribution of microchimeric cells can be envisioned to modulate health and disease in a similar manner to how commensal micro organisms are now recognized to control susceptibility to a wide variety of immunological and non-immunological disorders 75, 76 . Considering that the reservoir of microchimeric cells is more transferable and potentially more unstable in females than in males (FIG. 2) , the effects of microchimerism would be predicted to be more pronounced in females 63 . For example, a cross-sectional analysis of the prevalence of maternal and fetal micro chimeric cells in parous women found that MMC decreased with increasing parity 77 , which indicates the probable replacement of maternal microchimeric cells by fetal microchimeric cells during each successive pregnancy. Accordingly, the wider diversity and potential dynamic interplay between microchimeric cells of maternal and fetal origin, or genetically discordant fetal cells retained after each successive pregnancy, may contribute to the increased susceptibility of women during their reproductive years to autoimmune disorders and others diseases that are caused by aberrantly activated immune cells 78 . Extending the complexity of the microchiome is the possibility that pre-existing subsets of microchimeric cells retained in women from either previous pregnancies or their older siblings can be vertically transferred to offspring (FIG. 2) . For example, Y-chromosome DNA is frequently identified in the cord blood of younger female siblings with older brothers and among the tissues of adult women who have never given birth to a son 79 . Further highlighting the importance of sibling birth order, and hence unidirectional tolerance to sibling-derived microchimeric cells, is the reduced incidence of GVHD among individuals with haematological malignancy following stem cell transplants involving HLA-matched younger-sibling donors compared with older-sibling donors 80, 81 . However, these protective benefits of microchimerism were not associated with improved survival after stem cell transplantation in individuals with aplastic anaemia 82 , a finding that may reflect the contribution of other immunological mechanisms to this form of rejection, such as natural killer cell expression of discordant killer cell immuno globulin-like receptors 83 .
There is also the intriguing potential for maternal microchimeric cells to be transferred across generations from a maternal grandmother to her grandchild (FIG. 2) , which -similarly to other hereditary sources of genetically foreign cells -may instigate or protect against autoimmune disorders (as reviewed in REF. 63 ; TABLE 2). However, direct evidence to confirm the existence of grandmaternal microchimeric cells in secondgeneration offspring is still lacking, mainly owing to the lack of tools that enable the precise identification of these cells, which are likely to be very rare. In this regard, date-marking based on 14 C integration 84 -which identifies when DNA synthesis occurredcould be used to analyse the age, and hence the potential multi generational heritage, of microchimeric cells. Nonetheless, the accumulation of and dynamic interplay between genetically discordant, microchimeric cells within the same individual creates an exciting new framework that provides a view of immunological identity that extends beyond the traditional tenets of self versus non-self antigen distinction 1, 2 .
Microchimeric cells: helpful or harmful?
The highly conserved nature of microchimerism across placental mammalian species suggests that the enhanced genetic fitness associated with the persistence of microchimeric cells is likely to be shared by all mothers and their female offspring. However, the purposeful retention of microchimeric cells that reinforces fetal tolerance during future pregnancies also has the potential to provoke aberrant alloimmune activation, and suggests new ways in which to consider the pathogenesis of autoimmunity or idiopathic auto-inflammatory disorders. In turn, a more comprehensive analysis of the tissue distribution and phenotype of microchimeric cells, and their dynamic interplay with host cells, may reveal other non-reproductive benefits and harmful consequences that are associated with individuals being constitutively chimeric.
FMC in maternal autoimmunity and tissue homeo stasis.
There is a provocative association between increased FMC and greater susceptibility of women Nature Reviews | Immunology to various autoimmune disorders during their reproductive years (as reviewed in REFS 63, 67) . Most of these studies show increased numbers of fetal microchimeric cells in diseased tissue or in the circulation of women with autoimmunity, which suggests that alloreactivity to fetal microchimeric cells or tissue seeding by fetal adaptive immune cells may aggravate or initiate autoimmunity. For example, FMC is significantly increased in the blood of women with scleroderma compared with in the blood of healthy controls 85 . Interestingly, increased levels of FMC coincide with greater maternal-fetal HLA class II compatibility in women with scleroderma 85, 86 , which suggests that this MHC matching may promote the retention of fetal microchimeric cells by protecting them from rejection. However, because these fetal microchimeric cells express other alloantigens that are foreign to mothers, their presence can also cause low-grade inflammation and maternal susceptibility to immune-mediated tissue injury. Similarly, the enforced fetal tolerance that occurs in allogeneic pregnancies sired by males that express NIMAmatched MHC haplotypes 15 may promote increased levels of FMC and greater maternal susceptibility to auto immunity. Together, these findings suggest that fetal cells expressing foreign MHC alleles or other alloantigens that seed maternal tissues may be the target of maternal allo immunity, which is likely to be clinically indistinguishable from autoimmunity.
Given the lack of representative disease models that allow for the experimental manipulation of microchimeric cells, the causative relationship between increased FMC and maternal autoimmunity remains speculative. This uncertainty is compounded by a potential protective role of fetal microchimeric cells in tissue homeostasis and in the replacement of injured cells in diseased tissues (TABLE 2) . Another interesting consideration is that emerging data show that the risk of developing autoimmune disorders such as scleroderma, rheumatoid arthritis and multiple sclerosis decreases in women in line with increasing number of prior pregnancies [87] [88] [89] [90] [91] [92] . Although the number and diversity of fetal microchimeric cells were not tested in these studies, the benefits of prior pregnancy, and potentially an increasing number of prior pregnancies, in reducing the risk of developing autoimmunity may reflect the greater accumulation and heterogeneity of fetal microchimeric cells retained in mothers after each pregnancy.
The severity and relapse rate of pre-existing autoimmune disorders, such as multiple sclerosis and rheumatoid arthritis, are also reduced during pregnancy 16, 17 . These beneficial effects of pregnancy are most apparent during the last trimester when the levels of FMC are highest 16, 21, 93, 94 . In turn, the remission of multiple sclerosis and rheumatoid arthritis is often reversed shortly after parturition, which parallels the sharp numerical decline in fetal microchimeric cells 16, 17, 21 . Female reproductive hormones, the levels of which increase during pregnancy, probably contribute to these clinical phenotypes, as suggested by the fact that the relapse rate of multiple sclerosis is reduced in non-pregnant women who are administered exogenous oestriol 95 . A pregnancy-induced expansion of maternal T reg cell populations may mediate this crosstalk between female reproductive hormones and protection against autoimmune disease relapse, as glucocorticoid receptor stimulation of maternal T cells is necessary for the peripheral induction of T reg cell differentiation and for protection against paralysis in animal models of multiple sclerosis 96 . Thus, these associations highlight the need for additional studies that definitively establish the role of FMC in driving the expansion of maternal T reg cell populations during pregnancy.
Beyond the context of immunological tolerance, tissue seeding of fetal microchimeric cells that have multilineage potential can also ameliorate disease by replacing injured maternal cell subsets. For example, fetus-derived pancreatic acinar cells have been detected in mouse models of diabetes, and this suggests that cells of fetal origin can replace defective islet cells in maternal type 1 diabetes 97 . Likewise, beneficial properties of FMC have been described after non-immune tissue injury, including models of myocardial infarction or Parkinson • Priming the expansion of maternal T reg cell populations, and other suppressive adaptive immune components, with a specificity that averts maternal-fetal conflict during pregnancy [26] [27] [28] 36, 129 • Ameliorating organ-specific autoimmunity during pregnancy and after parturition 16, 17 • Replacing injured cells in diseased tissues [97] [98] [99] [100] [101] [102] [103] [104] [105] • Promoting the postpartum care of offspring 67 • Are a target of alloimmune inflammatory responses in the host 63, 85, 86 • Fetus-derived adaptive immune cells promote a graft-versus-host-like attack of host cells and tissues
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Maternal microchimeric cells in offspring
• Priming the expansion of fetal T reg cell populations, and other suppressive adaptive immune components, with a NIMA specificity that averts maternal-fetal conflict during pregnancy 12, 15, 61 • Replacing injured cells in diseased tissues [108] [109] [110] [111] • Replacing deficient or underdeveloped fetal immune cells [115] [116] [117] • Promoting immune cell development in offspring 8, 12, 48 • Are a target of alloimmune inflammatory responses in the host 63, 130 • Maternal adaptive immune cells promote a graft-versus-host-like attack of host cells and tissues 106, 107, 131 NIMA, non-inherited maternal antigen; T reg cell, regulatory T cell.
Maternal-fetal histocompatibility
The degree of similarity between genetically encoded MHC alleles in each motherchild pair.
disease, in which pluripotent fetal microchimeric cells are thought to differentiate into cell types that infiltrate and replace the injured cells in diseased tissues [98] [99] [100] [101] [102] [103] . The protective benefits associated with FMC may also be mediated by neoangiogenesis during wound healing 104, 105 . Interestingly, the deliberate seeding of fetal microchimeric cells into defined maternal tissues has also been proposed to promote the postpartum care of offspring (as reviewed in REF. 67 ). For example, the accumulation of fetal microchimeric cells in maternal breast tissue may promote lactation and in the brain may enhance maternal attention 67 . Thus, fetal microchimeric cells, and their likely greater accumulation and wider heterogeneity with increasing parity, could influence the health of mothers during and after pregnancy through both immune and non-immune pathways; this possibility requires further study in animal disease models that incorporate the manipulation of microchimeric cells.
MMC in the immunological development of offspring.
Increased levels of MMC have been observed in a wide variety of human autoimmune disorders, including type 1 diabetes, juvenile dermatomyositis, myo pathies, scleroderma, biliary atresia and neonatal lupus congenital heart block 23, 63 . This suggests that maternal microchimeric cells -similarly to fetal microchimeric cells in the mother -may be the targets of an alloimmune response by the offspring or may trigger an alloimmune reaction against genetically foreign antigens expressed by the offspring (TABLE 2) . Although alloimmunity mediated by maternal microchimeric cells
has not yet been conclusively demonstrated in humans, animal disease models suggest that allo reactive maternal T cells promote autoimmune diabetes 106 and intestinal inflammation 107 . Importantly, however, these potential harmful effects of maternal microchimeric cells are likely to be counterbalanced by the evolutionary advantages that are conferred by these cells in terms of the health of offspring. Together with the aforementioned crossgenerational reproductive benefits of NIMA-specific tolerance 15 , these health benefits include a regenerative function of maternal microchimeric cells that have multi lineage potential; for example, female insulinproducing cells have been detected in the pancreatic islets of men with type 1 diabetes 108, 109 . Other examples of maternal microchimeric cell-mediated protection against tissue injury occur in pityriasis lichenoides, in which maternal cells can adopt keratinocytic phenotypes 110 , and in neonatal lupus congenital heart block, in which maternal cells have the phenotype of cardiomyocytes 111 . However, despite these associations, the lack of tools for selectively manipulating maternal microchimeric cells within individual tissues precludes the definitive establishment of their beneficial properties and the exclusion of their potential role in instigating inflammation as a result of a loss of tolerance to these cells.
Despite similarities in the distribution and persistence of maternal and fetal microchimeric cells, there are inherent differences in the immunological maturity and responsiveness of the recipient host that these cell types initially encounter. Whereas fetal micro chimeric cells seed an immunologically mature mother, maternal microchimeric cells are transferred to the fetus before or during key milestones in immuno logical development 11, 12, 42, 45, 112, 113 (FIG. 3) . The potential protective effects of maternal microchimeric cells are indicated by their presence in primary and secondary lymphoid organs before the fetal immune system is fully developed in healthy and immune-deficient offspring 11, 12, 49, 114 . In human infants with severe combined immunodeficiency, the presence of expanded populations of circulating maternal T cells improves the health of offspring by augmenting host defence against microorganisms that cause opportunistic infection, such as Epstein-Barr virus 115 . Maternal microchimeric cells have also been shown to produce IgG in mouse offspring that are genetically deficient for B cells 116 , and to produce interleukin-2 (IL-2) in the thymus and spleen of IL-2-deficient offspring 117 . Although these observations show that maternal cells can replace missing fetal immune components in immune-deficient offspring, insights into the beneficial effects of maternal microchimeric cells on the physiological course of immune ontogeny remain sparse. Nonetheless, considering that a major threat to offspring survival in the neonatal period is caused by microbial infection, it is tempting to speculate that maternal microchimeric cells could accelerate the maturation of fetal immune cells by delivering essential growth and differentiation factors. Alternatively, the expanded accumulation of T reg cells specific for NIMAs may also promote the health of offspring by dampening inflammation induced by microbial colonization during the perinatal period, and by suppressing the aberrant immune responses that ultimately lead to allergy and autoimmunity 8, 118, 119 . This window of expanded tolerance in early development can also be exploited by microorganisms such as hepatitis B virus, which more efficiently establish persistent infection in offspring after vertical transmission from mothers 120 . The transfer and persistence of maternal microchimeric cells can be reciprocally influenced by genetic and external factors. For example, the extent of maternal-fetal histocompatibility has been shown to increase MMC in offspring 49, 121, 122 . Similarly, pertussis toxin-induced inflammation in mothers during pregnancy causes increased cellular trafficking across the placenta to the offspring 123 . Increased levels of maternal DNA are also found in offspring after intra-uterine fetal trauma induced by intrahepatic saline injection in mice 124 , and after in utero fetal surgical repair of spina bifida in humans 125 . Furthermore, given the known influences of maternal stress, infection and mal nutrition during pregnancy on the immunological development of the offspring 8 , understanding how these factors affect the number and phenotype of maternal cells that are transferred and retained in offspring may reveal innovative new strategies for improving the health of infants and children.
Outlook and future directions Important discoveries regarding the existence of immuno logical tolerance have historically been made by investigating 'nature's allograft': that is, the genetically foreign fetus [5] [6] [7] . Interestingly, in addition to the findings of these early studies, we now know that expanded tolerance during fetal development is not limited to antigens that are expressed by fraternal twin siblings 3 but also efficiently extends to NIMAs [50] [51] [52] . Similarly, partnerspecific protective benefits of prior pregnancy on reduced complications in future pregnancies suggest that tolerance retained in mothers also expands to encompass pre-existing fetal antigens 65, 66 . Thus, reproduction and pregnancy highlight the remarkable plasticity of immune tolerance that extends classical definitions of self versus non-self antigen distinction 1, 2 . But how and why is this expanded tolerance achieved? Persistent bidirectional tolerance in mothers and offspring after pregnancy is demonstrated by the long-term retention of microchimeric cells 63 . Interestingly, recent findings suggest that these genetically foreign cells are probably not the beneficiaries but rather the instigators of expanded immune tolerance 15 . Thus, the intentional transfer and retention of genetically foreign microchimeric cells force a reconsideration of how we define immunological identity in individuals, as the definition needs to include familially relevant antigens that are encoded by microchimeric cells. In turn, establishing how microchimeric cells prime expanded tolerance to evade rejection may reveal exciting new ways for us to reconceptualize how immunological tolerance naturally works.
With improved tools for the identification and experimental manipulation of rare microchimeric cells, important areas for future study will include investigating whether microchimeric cells randomly seed recipient tissues or are actively recruited to specific fetal and maternal organs; determining which chemoattractants instruct tissue-specific homing; and examining whether microchimeric cells require differentiation cues via co-stimulation, inflammatory mediators and/or growth factors to proliferate and acquire tolerogenic properties. Moreover, considering the dominant role that reproductive benefits have in driving trait selection, the protective effects of microchimeric cells in promoting the success of future pregnancies may outweigh their potential harmful roles in causing aberrant alloreactivity to genetically foreign cells. Thus, considering individuals as being constitutively chimeric -possessing a biologically active microchiome of genetically foreign cells -has exciting potential, with further study, not only to reveal new approaches for improving the outcomes of pregnancy, but also for developing innovative therapeutic solutions for other immunological problems such as autoimmunity and transplantation. Nature Reviews | Immunology . This seeding coincides with important milestones in the development of fetal and neonatal haematopoietic cells, including the development of central tolerance, and the differentiation of regulatory T (T reg ) cells in the thymus (tT reg cells) and periphery (pT reg cells) 42, 126, 127 . Evolutionary adaptations -including the emergence of immunosuppressive CD71 + erythroid cells and diminished responsiveness of neonatal immune cells -favour the development of immune tolerance in early postnatal development to avert pathological inflammation driven by commensal microbial colonization 119, 128 . Given the near-ubiquitous presence of maternal cells in these developing fetal tissues, and the notable short-term and long-term implications of impaired or delayed fetal-neonatal immune ontogeny, important areas for future investigation include how maternal microchimeric cells may affect functional haematopoiesis in offspring. CXCL8, CXC-chemokine ligand 8; MMC, maternal microchimerism; TCR, T cell receptor; T H 2, T helper 2.
